Ranitidine Carcinogenic Contaminants Investigation

Migliaccio & Rathod LLP is currently investigating manufacturers of the prescription and over-the-counter heartburn medication ranitidine, known by the brand name Zantac. The U.S. Food and Drug Administration (FDA) recently requested manufacturers pull the drug from the market, citing an ongoing investigation that found many ranitidine samples contained hazardous levels of the contaminant NDMA, a probable human carcinogen. Also known as N-nitrosodimethylamine, NDMA impurities can accrue in ranitidine products to levels that constitute a public health risk when stored over long periods of time and at higher-than-normal temperatures. The FDA further advised over-the-counter consumers to stop taking any ranitidine tablets or liquid medications and properly dispose of them. Prescription consumers should consult their doctors before cessation of use.

Have you taken ranitidine medications and fear you’ve been exposed to hazardous levels of NDMA?

If so, we would like to speak with you. Please complete the contact form on this page, send an email to [email protected] or call us at (202) 470-3520 for more information.

Committed to Consumer Protection

The lawyers at Migliaccio & Rathod LLP have years of experience in class action litigation against large corporations, including in cases involving defective products. More information about our current cases and investigations is available on our blog.